CIRM Funded Clinical Trials

A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1

Disease Area: 
Hearing Loss
Intellectual Disability
Metabolic Disorders
Vision Loss
Investigator:
Robert Hayes
Institution:
Immusoft Corporation
CIRM Grant:
CLIN2-14416
Award Value:
$8,000,000
Trial Sponsor:
Immusoft Corporation
Trial Stage: 
Phase 1
Trial Status: 
Launching
Targeted Enrollment:
N/A
  • Print
  • PDF version